Pre-clinical companies

Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: repairing inflammatory organ damage, chronic renal diseases, induced pluripotent stem cell (iPSC)-derived medicines, oncology and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.